Celldex Therapeutics (CLDX) Upgraded to “Sell” at BidaskClub

BidaskClub upgraded shares of Celldex Therapeutics (NASDAQ:CLDX) from a strong sell rating to a sell rating in a report published on Friday.

A number of other equities research analysts have also commented on the stock. HC Wainwright reiterated a buy rating on shares of Celldex Therapeutics in a report on Tuesday, November 7th. WBB Securities reiterated a buy rating and set a $10.00 price target on shares of Celldex Therapeutics in a report on Wednesday, December 6th. Finally, Cantor Fitzgerald reiterated a buy rating and set a $9.00 price target on shares of Celldex Therapeutics in a report on Tuesday, September 26th. Three investment analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. Celldex Therapeutics currently has an average rating of Hold and an average price target of $7.05.

Celldex Therapeutics (NASDAQ CLDX) traded down $0.02 during trading hours on Friday, reaching $3.05. 668,749 shares of the company were exchanged, compared to its average volume of 1,086,486. Celldex Therapeutics has a 52 week low of $2.20 and a 52 week high of $4.02. The company has a market cap of $417.48, a price-to-earnings ratio of -3.02 and a beta of 2.73.

Celldex Therapeutics (NASDAQ:CLDX) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.27) by $0.07. Celldex Therapeutics had a negative net margin of 1,088.58% and a negative return on equity of 46.94%. The company had revenue of $3.90 million during the quarter, compared to analyst estimates of $1.30 million. During the same period in the prior year, the business posted ($0.29) EPS. The firm’s revenue was up 77.3% compared to the same quarter last year. analysts expect that Celldex Therapeutics will post -0.93 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Celldex Therapeutics by 7.8% in the 2nd quarter. Vanguard Group Inc. now owns 9,774,858 shares of the biopharmaceutical company’s stock worth $24,143,000 after purchasing an additional 708,095 shares in the last quarter. Meditor Group Ltd raised its holdings in Celldex Therapeutics by 8.8% in the 3rd quarter. Meditor Group Ltd now owns 6,312,700 shares of the biopharmaceutical company’s stock worth $18,054,000 after purchasing an additional 512,700 shares in the last quarter. Northern Trust Corp raised its holdings in Celldex Therapeutics by 12.2% in the 2nd quarter. Northern Trust Corp now owns 2,020,797 shares of the biopharmaceutical company’s stock worth $4,992,000 after purchasing an additional 219,661 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Celldex Therapeutics by 3.6% in the 3rd quarter. Dimensional Fund Advisors LP now owns 861,790 shares of the biopharmaceutical company’s stock worth $2,465,000 after purchasing an additional 29,604 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its holdings in Celldex Therapeutics by 3.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 622,430 shares of the biopharmaceutical company’s stock worth $1,780,000 after purchasing an additional 21,905 shares in the last quarter. Institutional investors and hedge funds own 52.46% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was published by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this story on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The correct version of this story can be accessed at https://sportsperspectives.com/2018/01/06/celldex-therapeutics-cldx-upgraded-to-sell-at-bidaskclub.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Analyst Recommendations for Celldex Therapeutics (NASDAQ:CLDX)

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply